The acquisition strengthens HiFiBiO Therapeutics’ strategic focus on identifying first-in-class targets for multiple immune cell types, as well as applying industry-leading technologies to develop diverse antibody therapeutics. Specific
The study has achieved the primary endpoint by demonstrating Kadcyla as a single agent significantly reduced the risk of disease recurrence or death compared to Herceptin as an
aGvHD is a leading cause of death following an allogeneic stem cell transplant due to the transplanted immune cells attacking the patient’s tissues. It results in a very
This divestiture is being done by way of slump sale (as a going concern) and includes all related fixed assets (land and building), current assets, current liabilities, and
As part of the deal, Adynxx stockholders will become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis. The public clinical-stage pharmaceutical firm will involve
The regulator’s Oncologic Drugs Advisory Committee voted unanimously recommending approval of CT-P10, a proposed monoclonal antibody (mAb) biosimilar to Rituxan, to treat adult patients in three proposed indications.
The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma. MaxCyte CEO Doug Doerfler said: “The initiation of
The collaboration will leverage Jnana’s proprietary drug discovery platform across the solute carrier (SLC) family of transporters and Neurocrine’s research and development expertise in CNS disorders to advance
The trial showed that Stelara induced clinical remission in a significantly greater proportion of UC patients at week 8 compared to placebo at both doses studied. Major secondary
Designed to Current Good Manufacturing Practices (cGMP) specifications and certified by the Belgian Federal Agency for Medicines and Healthcare Products, the new €5m facility, adjacent to its headquarters
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.